Crossmark Global Holdings Inc. boosted its holdings in Smith & Nephew plc (NYSE:SNN) by 0.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 350,540 shares of the medical equipment provider’s stock after purchasing an additional 3,291 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Smith & Nephew were worth $12,272,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. Parametric Portfolio Associates LLC increased its stake in Smith & Nephew by 17.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 516,794 shares of the medical equipment provider’s stock worth $18,811,000 after buying an additional 76,003 shares in the last quarter. Jane Street Group LLC increased its stake in Smith & Nephew by 109.1% in the 3rd quarter. Jane Street Group LLC now owns 340,327 shares of the medical equipment provider’s stock worth $12,388,000 after buying an additional 177,546 shares in the last quarter. FDx Advisors Inc. increased its stake in Smith & Nephew by 39.5% in the 3rd quarter. FDx Advisors Inc. now owns 27,490 shares of the medical equipment provider’s stock worth $1,001,000 after buying an additional 7,790 shares in the last quarter. Atlantic Trust Group LLC purchased a new stake in Smith & Nephew in the 3rd quarter worth $1,768,000. Finally, Cambiar Investors LLC boosted its holdings in shares of Smith & Nephew by 2.1% during the 3rd quarter. Cambiar Investors LLC now owns 5,398,020 shares of the medical equipment provider’s stock valued at $196,488,000 after purchasing an additional 109,105 shares during the last quarter. Institutional investors and hedge funds own 6.56% of the company’s stock.
Several research analysts have commented on SNN shares. Morgan Stanley downgraded shares of Smith & Nephew from an “overweight” rating to an “equal weight” rating in a report on Monday, December 11th. Canaccord Genuity reissued a “buy” rating and set a $45.00 price objective on shares of Smith & Nephew in a report on Friday, January 5th. JPMorgan Chase & Co. raised shares of Smith & Nephew from a “neutral” rating to an “overweight” rating in a report on Thursday, January 25th. Finally, Zacks Investment Research downgraded shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $44.00.
Smith & Nephew plc (SNN) opened at $34.44 on Tuesday. Smith & Nephew plc has a 1-year low of $29.76 and a 1-year high of $40.43. The company has a current ratio of 2.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.
ILLEGAL ACTIVITY WARNING: This report was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thestockobserver.com/2018/02/06/crossmark-global-holdings-inc-has-12-27-million-holdings-in-smith-nephew-plc-snn.html.
Smith & Nephew Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN).
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.